The ELF™ Blood Test
"The discovery of the ELF markers represents a significant advancement in the diagnosis of patients with liver disease. Of particular benefit, the ELF test can help diagnose patients with mild-to-moderate liver fibrosis, which is usually asymptomatic, so that clinicians are able to intervene before significant damage to the liver occurs."
William Rosenberg, MD
Centre for Hepatology University
NICE Guidelines Now Include ELF Blood Test!
The National Institute for Health and Care Excellence provides evidence-based guidelines across healthcare and is used by local authorities to inform healthcare-related decisions. NICE has recently recommended the use of the ELF test to test for and monitor advanced liver fibrosis in people diagnosed with Non Alcoholic Fatty Liver Disease (NAFLD).
Link to NICE Guidelines: NICE Guidelines: Non-Alcoholic Fatty Liver Disease: assessment and management.
What is the ELF Blood Test?
ELF stands for Enhanced Liver Fibrosis. The ELF Blood Test combines three serum biomarkers, which have been shown to correlate to the level of liver fibrosis assessed by liver biopsy. These biomarkers include:
- Hyaluronic acid (HA)
- Procollagen III amino terminal peptide (PIIINP)
- Tissue inhibitor of metalloproteinase 1 (TIMP-1)
The algorithm measures each of these markers by immunoassay, to create an ELF Score, from which a designation for fibrosis severity can be determined. The ELF Blood Test can be performed in a physician’s office or health center.
For more details about the ELF Blood Test on the ADVIA Centaur systems, please refer to the ELF Specification Sheet. Download ELF Specification Sheet 0.3 MB
Information regarding the ELF Blood Test and the relationship to liver fibrosis can be found in the Physician Brochure. Download ELF Physician Brochure 2.1 MB
Bringing The ELF Blood Test to your Laboratory
If you are interested in bringing the ELF Blood Test to your laboratory, please contact your local Siemens Healthineers representative.
* Not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.